Why the study?
Does neuregulin improve cardiac function via cMLCK-dependent RLC phosphorylation in cMLCK knockout mice?
Does neuregulin improve cardiac function via cMLCK-dependent RLC phosphorylation in cMLCK knockout mice?
This preclinical study aims to determine if cardiac myosin light chain kinase is mechanistically necessary for neuregulin-induced improvements in cardiac function.
Answers are grounded in this paper and cite their sources.
Does not inform neuregulin use in patients; leaves open cMLCK dependence in cardiac models.
Background: Activation of ErbB2/4 receptor tyrosine kinases in cardiomyocytes by neuregulin treatment is associated with improvement in cardiac function, supporting its use in human patients with heart failure despite the lack of a specific mechanism. Neuregulin infusion in rodents increases cardiac myosin light chain kinase (cMLCK) expression and cardiac myosin regulatory light chain (RLC) phosphorylation which may improve actin-myosin interactions for contraction. We generated a cMLCK knockout mouse to test the hypothesis that cMLCK is necessary for neuregulin-induced improvement in cardiac function by increasing RLC phosphorylation.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: